Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Intradigm Corporation

Request full access

Biotechnology company developing systematic rna interference therapeutics

Palo Alto, United StatesFounded 2000Biotech & Life Sciences

About Intradigm Corporation

Intradigm Corporation operated as a privately held biotechnology company, established in 2000, that focused on the development of RNA interference (RNAi) therapeutics. The firm's primary objective was to address diseases with significant unmet medical needs, with an initial concentration on oncology. The company was co-founded by Dr. Patrick Y. Lu, Martin Woodle, Puthupparampil Scaria, and Wei-Wu He. Dr. Lu, who served as Executive Vice President, brought over a decade of pharmaceutical industry experience in nucleic acid therapeutics and cancer drug development from his time at Novartis and Digene.

Intradigm's business strategy centered on leveraging its proprietary RNAi therapeutic platform to create an internal product pipeline and establish high-value partnerships with pharmaceutical companies. The company's revenue model was based on collaborations and milestone payments from these partnerships. The core of its technology was a comprehensive platform that included proprietary siRNA sequences, innovative siRNA structural features, and a unique delivery system. This platform was designed to overcome a major hurdle in the field: the safe and effective systemic delivery of RNAi molecules to targeted diseased tissues. The company developed a ligand-targeted nanoparticle system, known as RNAi Nanoplex, which utilized biodegradable polymers for the delivery of its therapeutics. This system aimed to enable functional delivery of siRNA molecules while enhancing their bioavailability and intracellular uptake. Intradigm established a portfolio of siRNA sequences against more than 50 oncology and other disease targets and held an exclusive license to the Zamore patent family from the University of Massachusetts, covering broad structural features of siRNA design.

Throughout its operation, Intradigm secured significant funding to advance its research and development. In May 2006, the company completed a $16 million Series A financing round co-led by Alta Partners and Frazier Healthcare Ventures. This was followed by a Series B financing round that ultimately totaled $21.4 million, with investors including Lilly Ventures, Roche Venture Fund, and Astellas Venture Management. In December 2009, Intradigm announced its merger with the UK-based Silence Therapeutics plc. The merger, completed in January 2010, created an enlarged company, retaining the Silence Therapeutics name, with an expanded portfolio of RNAi technologies and a strengthened position in the RNAi therapeutics market. Following the merger, Intradigm's shareholders owned 36.6 percent of the new entity.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
5
Open positions
None listed
Dealroom signal
52.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Dec 2009 $0 — Silence Therapeutics —
SERIES B✓Equity / VC Jan 2009 $21M $86M Lilly Ventures · MP Healthcare Venture Management · Frazier Healthcare Partners · Alta Partners —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Intradigm Corporation website traffic

Latest recorded traffic for Intradigm Corporation is 0 monthly website visits. Intradigm Corporation's team declined 16.7% over the past year.

Latest monthly visits0 1-year team growth-16.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Intradigm Corporation in the Palo Alto ecosystem

Live from Dealroom

The Intradigm Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Frazier Healthcare Partners
  • Alta Partners
  • ETP Ventures
  • Novartis Venture Fund
  • Astellas Venture
  • Lilly Ventures
  • MP Healthcare Venture Management
  • Roche Venture Fund

Other known investors1 additional known investor

  • Silence Therapeutics
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Palo Alto HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Intradigm Corporation on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Intradigm Corporation’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.